Paul Tudor Jones’s Crinetics Pharmaceuticals CRNX Stock Holding History

Paul Tudor Jones’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-46,021	Closed	-$1.67M	–	3673
2026 Q1	$1.67M	Buy	+46,021	New	+$2.06M	﹤0.01%	1984
2024 Q1	–	Sell	-39,764	Closed	-$1.41M	–	2311
2023 Q4	$1.41M	Buy	39,764 +6,764	+20%	+$207K	0.01%	1278
2023 Q3	$981K	Buy	33,000 +5,972	+22%	+$123K	0.01%	1308
2023 Q2	$487K	Buy	+27,028	New	+$539K	0.01%	1726
2022 Q4	–	Sell	-26,753	Closed	-$525K	–	2466
2022 Q3	$525K	Buy	+26,753	New	+$546K	0.01%	1364

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's CRNX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 46,021 shares — an estimated $1.67M sold.

Paul Tudor Jones first reported a position in CRNX in Q3 2022 and held it in 5 quarters. The position peaked at $1.67M in Q1 2026. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Paul Tudor Jones reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 46,021 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.67M.
Paul Tudor Jones first reported a position in Crinetics Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Paul Tudor Jones's Crinetics Pharmaceuticals position peaked at $1.67M in Q1 2026.
264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.